Last reviewed · How we verify
regorafenib tablet
At a glance
| Generic name | regorafenib tablet |
|---|---|
| Also known as | STIVARGA |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (PHASE2)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Regorafenib for Recurrent Meningioma (MIRAGE Trial) (PHASE2)
- A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs (PHASE3)
- Phase II Study of Regorafenib as Maintenance Therapy (PHASE2)
- Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib (PHASE2)
- Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients (PHASE2)
- Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- regorafenib tablet CI brief — competitive landscape report
- regorafenib tablet updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI